MiCAN Technologies
MiCAN Technologies has technologies and licenses to produce high function human myeloid lineage cells (Mylc) from human iPS cells. The development and the feasibility studies to launch the cMylc has been conducted with a collaboration to the Research Institute for Microbial Diseases at Osaka University.
Business information
Company name
MiCAN Technologies
Established
2016
Location
Kyoto, JP
Spinout from
Independent
Other location(s)
Kobe, JP
Technology validation
TRL
7
Value of patent(s)
No data
Business stage
Spinout / Seed fund stage
Target exit
IPO in other country
Next investment requirement
Message to the business partners
MiCAN is looking for global R&D partners to evaluate our iPS derived dendric myeloid cells in the applications of dengue virus and COVID-19 (SARS-CoV-2) research. Also looking for global supply chain partners (distributors) to handle our ready-to-use kit accessible to the global scientists.
Company URL
Key literatures